U22, a protocol to quantify symptoms associated with supraventricular tachycardia

Area of Science:

• Cardiology
• Medical Technology

Background:

• Supraventricular tachyarrhythmias (SVTA) management primarily focuses on symptomatic relief.
• Existing quality-of-life measures like SF-36 do not adequately capture specific paroxysmal SVTA symptoms.
• A novel U22 protocol was developed to assess arrhythmia impact on well-being and symptom characteristics.

Purpose of the Study:

• To evaluate the utility of the U22 protocol in quantifying symptoms associated with SVTA.
• To compare the U22 protocol's effectiveness against the SF-36 questionnaire in SVTA patients.

Main Methods:

• Eighty-eight patients undergoing catheter ablation for SVTA were assessed using both U22 and SF-36 protocols.
• The U22 protocol utilizes discrete 0-10 scales to measure well-being, symptom intensity, and episode characteristics.
• SF-36 assessed general quality of life through physical and mental component summaries.

Main Results:

• U22 scores indicated significant negative impacts on well-being (7.5/10) and high discomfort during arrhythmia (8.0/10).
• The intensity of dominant symptoms was rated very high (9.7/10) by U22.
• Multiple dominant symptoms, identified by U22 in 29% of patients, correlated with lower SF-36 general well-being scores.

Conclusions:

• The U22 protocol is a valuable tool for quantifying patient-reported symptoms in SVTA.
• U22 provides a more individualized and detailed assessment of SVTA symptom burden compared to SF-36.